Keystone Symposia | Scientific Conferences on Biomedical and Life Science Topics

HIV Vaccines: Progress and Prospects (X7)

Organizer(s): Dan H. Barouch, John R. Mascola and M. Juliana McElrath
March 27 - April 1, 2008
Fairmont Banff Springs · Banff, Alberta
Abstract Deadline: November 28, 2007
Late Abstract Deadline: December 28, 2007
Scholarship Deadline: November 28, 2007
Early Registration Deadline: January 28, 2008

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation; Sponsored by Wyeth Vaccines Research

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this educational activity for a maximum of 28-35 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

To receive CME credits, mark the box on the registration form, and pay the additional $50.00.

Joint meeting: HIV Pathogenesis (X8)
NOTE: Registration for meeting allows attendance at joint meeting (pending space availability).

This meeting took place in the 2008 season.

Listed below are current meetings that are similar to this meeting in nature/content:

HIV Vaccines (X5)
March 21 - 26, 2010

For a complete list of the meetings for the upcoming/current season,
see our meeting list, or search for a meeting.

Summary of Meeting
The development of a safe and effective HIV-1 vaccine remains one of the highest research priorities. Several vaccine candidates are currently being evaluated in large-scale clinical trials, but numerous challenges remain. Immunogens that elicit broadly reactive neutralizing antibodies remain elusive. Vaccine vectors that induce cellular immune responses will likely require considerable improvement. Immune correlates of protection are not clearly defined, and the challenges of extensive worldwide viral sequence diversity remain. In this Keystone Symposia meeting, leading experts in the field will discuss recent advances in novel vaccine approaches, humoral and cellular immunity, immune correlates of protection, and early and late phase clinical trials. Vaccine-elicited immunity, translational vaccine development, and the Global HIV/AIDS Vaccine Enterprise will be highlighted.

Thursday, March 27
3:00 - 7:30 PM	Registration	Van Horne Ballroom Foyer
6:30 - 7:30 PM	Refreshments	Van Horne Ballroom Foyer
7:30 - 9:30 PM	Keynote Session (Joint)	Van Horne Ballroom AB
	* Steven M. Wolinsky, Northwestern University

	Henry A. Erlich, Roche Molecular Systems HLA Allelic and Haplotypic Diversity and Host Immunity

	* Dan H. Barouch, Beth Israel Deaconess Medical Center
	Lawrence Corey, University of Washington HIV Vaccines: The Way Forward
Friday, March 28
7:00 - 8:00 AM	Breakfast	New Brunswick, Alberta, Cascade
8:00 - 11:00 AM	Biology of Transmission (Joint)	Van Horne Ballroom AB
	* Steven M. Wolinsky, Northwestern University
	Ashley T. Haase, University of Minnesota Sexual Mucosal Transmission
	Daniel C. Douek, NIAID, National Institutes of Health Immune Events in the HIV-Infected Gut

	Thomas J. Hope, Northwestern University, Feinberg School of Medicine Analysis of the Early Interactions of HIV with Human Cervical Explants and the Rhesus Macaque Female Genital Tract: The First 4 Hours of Virus Exposure
	James Arthos, National Institutes of Health Short Talk: HIV-1 Envelope Binds to and Signals through alpha4beta7 Integrin, the Gut Mucosal Homing Receptor for Peripheral T Cells
	Frank Wegmann, University of Oxford Short Talk: Combining HIV Antigens and Polyanionic Microbicides to Induce High Levels of Mucosal Env-Specific Antibodies
9:20 - 9:40 AM	Coffee Break	Van Horne Ballroom Foyer
11:00 AM - 1:00 PM	Poster Setup	New Brunswick, Alberta, Cascade
1:00 - 10:00 PM	Poster Viewing	New Brunswick, Alberta, Cascade
2:30 - 4:30 PM	Workshop 1 : Novel Vaccines and Adjuvants	Van Horne Ballroom C
	* Rama Rao Amara, Emory University
	* Robert A. Seder, NIAID, National Institutes of Health
	Tomas Hanke, Weatherall Institute of Molecular Medicine Development of a Universal T Cell Vaccine
	Antu K. Dey, Weill Medical College of Cornell University N-Terminal Substitutions in HIV-1 gp41 Reduce the Expression of non-Trimeric Envelope Glycoproteins on the Virus
	Gerald Kimani Chege, University of Cape Town A Pantothenate Auxotrophic Strain of BCG Expressing HIV-1 Gag Induces Cellular Responses in Baboons, which are Efficiently Boosted by HIV-1 Pr55gag VLPs
	Mario Roederer, National Institutes of Health Fine Aerosol Adenovirus Vaccination against SIV and Tuberculosis in Rhesus Macaque
	David B. Weiner, University of Pennsylvania School of Medicine Induction of Potent T Cell Immunity in Macaques by EP DNA + Molecular Adjuvants, Comparison of -Specific Responses Induced by Co-Vaccination of SIV DNA + Plasmid IL-12, IL-15 or RANTES in Rhesus Macaques
	Sean X. Du†, Maxygen Directed Molecular Evolution Created Genetic and Antigenic Diversity and Improved Overall Immunogenicity of HIV-1 gp120 Immunogen
	Mattias Forsell, Karolinska Institutet Elicitation of Co-Receptor Site Directed Antibodies against HIV-1 is caused by Primary Receptor Binding to the Viral Envelope Glycoproteins
4:30 - 5:00 PM	Coffee Available	Van Horne Ballroom Foyer
5:00 - 7:30 PM	Progress in Clinical Trials of HIV Vaccines	Van Horne Ballroom C
	* Peggy Johnston, NIAID, National Institutes of Health

	Susan P. Buchbinder, San Francisco Department of Public Health Primary Efficacy Results from the STEP Study (Merck V520 Protocol 023/HVTN 502)—a Phase II Test-of-Concept Trial of the MRKAd5 HIV-1 gag/pol/nef Trivalent Vaccine
	M. Juliana McElrath, Fred Hutchinson Cancer Research Center T Lymphocyte Responses Elicited by Current Vaccines
	Gary J. Nabel, National Institutes of Health Criteria for Advancement of Novel Vaccine Candidates

	William Snow, AIDS Vaccine Advocacy Coalition Short Talk: STEP-ing Forward: Community Perspectives on Communication and Decision-Making in the MRK-Ad5 Trials
	Harriet L. Robinson, Yerkes National Primate Research Center of Emory University Short Talk: GeoVax Clade B DNA/MVA HIV/AIDS Vaccine is well Tolerated and Immunogenic when Administered to Healthy Seronegative Adults (HVTN 065 part A)
	Laura Papagno, Laboratoire d'Immunologie Cellulaire, INSERM U543 Short Talk: Comprehensive Analysis of Virus-Specific CD8+ and CD4+ T Cells Provides Clues for the Failure of Therapeutic Immunization with ALVAC-HIV (vCP1452) Vaccine
7:15 - 8:15 PM	Social Hour w/ Lite Bites	New Brunswick, Alberta, Cascade
7:30 - 10:00 PM	Poster Session 1	New Brunswick, Alberta, Cascade
Saturday, March 29
7:00 - 8:00 AM	Breakfast	New Brunswick, Alberta, Cascade
8:00 - 8:20 AM	Special Lecture	Van Horne Ballroom C
	Alan Bernstein, Global HIV Vaccine Enterprise Special Lecture
8:00 - 11:00 AM	Optimization of Vectors and T Lymphocyte Responses	Van Horne Ballroom C
	* Nina Russell, Bill & Melinda Gates Foundation



	Giuseppe Pantaleo, Centre Hospitalier Universitaire Vaudois Novel Poxvirus Vectors
	Danilo R. Casimiro, Merck Research Laboratories What's Next After STEP? Implications on Vaccine Design
	Dan H. Barouch, Beth Israel Deaconess Medical Center Novel Adenovirus Vector-Based Vaccines for HIV-1
	Stephen C. De Rosa, University of Washington, Fred Hutchinson Cancer Research Center Short Talk: Kinetics of T Cell Responses to Vaccination for HIV with Heterologous DNA Prime-rAd5 Boost Contrasted with Homologous rAd5 Prime-Boost
	Rama Rao Amara, Emory University Short Talk: Preexisting Immunity to Vaccinia Reduces the Frequency of SIV-Specific CCR-5+ve but not CCR-7+ve CD4 T Cells Elicited by a DNA/MVA Vaccine and Enhances the Control of SIV251 Challenge
9:20 - 9:40 AM	Coffee Break	Van Horne Ballroom Foyer
11:00 AM - 1:00 PM	Poster Setup	New Brunswick, Alberta, Cascade
1:00 - 10:00 PM	Poster Viewing	New Brunswick, Alberta, Cascade
2:30 - 4:30 PM	Workshop 2: Mucosal/Innate Immunity	Van Horne Ballroom C
	* M. Juliana McElrath, Fred Hutchinson Cancer Research Center
	* Karin Loré, Karolinska Institutet
	Kimberly Ann Schoenly, University of Pennsylvania Systemic and Mucosal Immune Responses Elicited by Electroporation Delivered Mucosal Targeting Chemokine DNA Vaccines in Mice and Macaques
	David R. Kaufman, Beth Israel Deaconess Medical Center, Harvard Medical School Systemic Vaccination with Hetrologous Recombinant Adenovirus Prime-Boost Regimens Elicits Potent and Durable Mucosal Immunity
	Cornelia Gujer, Karolinska Institutet Dendritic Cell Mediated Support of Human B Cell Responses Via Toll-Like Receptor Ligands
	Kathlyn Santos, NIAID, National Institutes of Health Immunomodulation of Human Dendritic Cells by MVA and Ad5 Vaccine Vectors
	Elizabeth Rhee, Beth Israel Deaconess Medical Center Rare Serotype Recombinant Adenovirus Vaccine Vectors Elicit Expression of Type I Interferon
	Salix Boulet, McGill University Increased Expression of KIR3DL1 Subtypes and HLA-B57 in HIV Exposed Uninfected (EU) versus HIV Susceptible Individuals
	Patrice Debré, Hopital Pitie Salpetriere A New Concept for HIV Vaccine Preventing CD4 T Cell Depletion
4:30 - 5:00 PM	Coffee Available	Van Horne Ballroom Foyer
5:00 - 7:15 PM	Prospects for Generating Broad Neutralizing Antibody Responses	Van Horne Ballroom C
	* John R. Mascola, NIAID, National Institutes of Health
	Peter D. Kwong, Vaccine Research Center, National Institutes of Health CD4-Binding-Site Antibodies: Prospects, Complications and Crystallographic Analyses
	Munir Alam, Duke Human Vaccine Institute The Role of Hydrophobic CDRH3 Loops of the Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 in Binding gp41, Lipids and in HIV-1 Neutralization

	Quentin J. Sattentau, Sir William Dunn School of Pathology Novel Formulation, Adjuvantation and Delivery Strategies for Inducing Env-Specific Antibodies

	James E. Robinson, Tulane University Health Sciences Center Short Talk: SHIV-Infected Rhesus Macaques Develop Antibodies Recognizing Quaternary Epitope(s) Exposed on Autologous Virus Particles
	Nicole A. Doria-Rose, National Institute of Allergy and Infectious Diseases, National Institutes of Health Short Talk: Frequency and Phenotype of HIV gp120-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies
7:15 - 8:15 PM	Social Hour w/ Lite Bites	New Brunswick, Alberta, Cascade
7:30 - 10:00 PM	Poster Session 2	New Brunswick, Alberta, Cascade
Sunday, March 30
7:00 - 8:00 AM	Breakfast	New Brunswick, Alberta, Cascade
8:00 - 11:00 AM	Protection Against Transmission of Mucosal Viruses: What Can Be Learned?	Van Horne Ballroom C
	* Mario Roederer, National Institutes of Health
	Janine T. Bryan, Merck HPV Vaccine
	Harry B. Greenberg, Stanford University Rotavirus Pathogenesis and Vaccination-The Second Time is a Charm
	Lawrence Corey, University of Washington The HSV-HIV Connection: What Similarities Exist for Vaccine Development
	Maria Grazia Pau, Crucell Holland B.V. Flu, TB

	Meritxell Genescà, University of California, Davis Short Talk: SIV-specific CD8+ T Cells Mediated Protection from Uncontrolled Viral Replication after Vaginal Challenge in Live-Attenuated Immunized Rhesus Macaques
9:20 - 9:40 AM	Coffee Break	Van Horne Ballroom Foyer
11:00 AM - 1:00 PM	Poster Setup	New Brunswick, Alberta, Cascade
1:00 - 10:00 PM	Poster Viewing	New Brunswick, Alberta, Cascade
4:30 - 5:00 PM	Coffee Available	Van Horne Ballroom Foyer
5:00 - 7:00 PM	Viral Control (Joint)	Van Horne Ballroom
	* Dan H. Barouch, Beth Israel Deaconess Medical Center
	Andrew J. McMichael, John Radcliffe Hospital Cellular Immune Responses before and during Early HIV Infection
	Bruce D. Walker, Massachusetts General Hospital Durable Control of HIV Replication

	Douglas D. Richman, University of California, San Diego Neutralizing Antibody in the Control of HIV Infection
	Galit Alter, Massachusetts General Hospital Short Talk: Specific Expansion of Highly Functional KIR+ NK Cells during Acute HIV-1 Infection
7:00 - 8:00 PM	Social Hour w/ Lite Bites	New Brunswick, Alberta, Cascade
7:30 - 10:00 PM	Poster Session 3	New Brunswick, Alberta, Cascade
Monday, March 31
7:00 - 8:00 AM	Breakfast	New Brunswick, Alberta, Cascade
8:00 - 11:15 AM	Interface Between Immunology and Vaccine Design (Joint)	Van Horne Ballroom
	* M. Juliana McElrath, Fred Hutchinson Cancer Research Center

	Rafi Ahmed, Emory University School of Medicine CD8 T Cell Memory
	David I. Watkins, University of Wisconsin-Madison The Thorny Issue of Heterologous Challenge
	Bali Pulendran, Emory University Modulating Vaccine Responses with Innate Immunity
	Claire A. Chougnet, Cincinnati Children's Hospital Medical Center Interactions between Regulatory T Cells and HIV: A Complex Balancing Act
	April L. Ferre, University of California, Davis Short Talk: Polyfunctional T-Cells in the Rectal Mucosa of HIV Controllers
	Natalie A. Hutnick, University of Pennsylvania Short Talk: T-Cell Responses in Healthy Adults to Replication Deficient AdHu5 Vector
9:20 - 9:40 AM	Coffee Break	Van Horne Ballroom Foyer
4:30 - 5:00 PM	Coffee Available	Van Horne Ballroom Foyer
5:00 - 7:00 PM	Correlates of Immune Protection	Van Horne Ballroom C

	* John R. Mascola, NIAID, National Institutes of Health
	Louis J. Picker, Oregon Health & Science University Live Attenuated Vaccines

	R. Paul Johnson, Harvard Medical School Protection Against Mucosal SIV Transmission
	Rafick-Pierre Sekaly, University of Montreal Systems Biology Approaches to Understanding Memory T Cells Development and Defects
	Qingsheng Li, University of Minnesota Short Talk: Divergent Host Transcriptional Profiles in Lymphatic Tissues of Sooty Mangabeys and Rhesus Macaques Infected with Simian Immunodeficiency Viruses
7:15 - 8:15 PM	Social Hour w/ Lite Bites	New Brunswick, Alberta, Cascade
8:00 - 11:00 PM	Entertainment	New Brunswick, Alberta, Cascade
Tuesday, April 1
	Departure

*Session Chair †Speaker invited, not yet responded.